Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | Blood group genotyping program to improve transfusion outcomes in hemoglobinopathies

Sara Trompeter • 26 Oct 2023
ASCAT 2023
Anemias Non-Malignant Rare Diseases Sickle Cell Disease Thalassemia

Sara Trompeter, MD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the implementation of the Sickle Cell and Thalassemia Blood Group Genotyping Program into healthcare systems. Sponsored by NHS England, this program encourages patients with sickle cell disease (SCD), thalassemia, and rare inherited anemia to participate, in order to enhance donor compatibility for improved transfusion outcomes. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sara Trompeter

1:29
Diverse participation in SCD blood group genotyping for improved transfusion outcome
Sara Trompeter • 26 Oct 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A two-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals